Stay updated with breaking news from Phase 3 Studies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.
In the context of frontline treatment strategies in advanced HCC, expert oncologists review clinical research in systemic immunotherapy approaches.
– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 – – Agios to Host Investor Webcast Today at 7:30 a.m. ET – CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today reported a full analysis of updated data, including patient-reported outcome (PRO) measures,